Current misconceptions in diagnosis and management of iron deficiency

Blood Transfusion

Volumn 15, Issue 5, 2017, Pages 422-437

  Muñoz, Manuel ^a   Gómez Ramírez, Susana ^b   Besser, Martin ^c   Pavía, José ^a   Gomollón, Fernando ^d   Liumbruno, Giancarlo M ^e   Bhandari, Sunil ^f   Cladellas, Mercé ^g   Shander, Aryeh ^h   Auerbach, Michael ⁱ  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^g HOSPITAL DE L ESPERANÇA   (Spain)

^h ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

ⁱ GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaemia; Intravenous iron; Iron deficiency; Misconceptions; Oral iron

Indexed keywords

FERRITIN; IRON;

ANAPHYLAXIS; CONSENSUS; EVIDENCE BASED PRACTICE; FERRITIN BLOOD LEVEL; HEALTH CARE SYSTEM; HUMAN; INFECTION RISK; INTERVENTION STUDY; IRON DEFICIENCY; OXIDATIVE STRESS; PREMEDICATION; REVIEW; THERAPEUTIC MISCONCEPTION; BLOOD; DEFICIENCY; DIAGNOSTIC ERROR; IRON DEFICIENCY ANEMIA;

ANEMIA, IRON-DEFICIENCY; DIAGNOSTIC ERRORS; EVIDENCE-BASED PRACTICE; HUMANS; IRON;

EID: 85026648431     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2017.0113-17     Document Type: Review

References (170)

1. Kassebaum NJ, Jasrasaria R, Naghavi M., et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood 2014; 123: 615-24.
2. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015; 372: 1832-43.
3. Auerbach M, Adamson JW How we diagnose and treat iron deficiency anemia. Am J Hematol 2016; 91: 31-8.
4. Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008; 103: 1299-307.
5. Muñoz M., Gómez-Ramírez S, Kozek-Langeneker S, et al. 'Fit to fly': overcoming barriers to preoperative haemoglobin optimization in surgical patients. Br J Anaesth 2015; 115: 15-24.
6. Muñoz M., Acheson AG, Auerbach M, et al International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia 2017; 72: 233-47.
7. Muñoz M., Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol 2011; 64: 287-96.
8. Mast AE, Blinder MA, Gronowski A.M., et al. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem 1998; 44: 45-51.
9. World Health Organization. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Vitamin and Mineral Nutrition Information System. Geneva: WHO, 2011.
10. Mast AE, Blinder MA, Dietzen DJ Reticulocyte hemoglobin content. Am J Hematol 2008; 83: 307-10.
11. Thomas D.W., Hinchliffe RF, Briggs C, et al.; British Committee for Standards in Haematology. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol 2013; 161: 639-48.
12. Martin-Cabrera P., Hung M, Ortmann E., et al. Clinical use of low haemoglobin density, transferrin saturation, bone marrow morphology, Perl's stain and other plasma markers in the identification of treatable anaemia presenting for cardiac surgery in a prospective cohort study. J Clin Pathol 2015; 68: 923-30.
13. NICE guideline. Chronic kidney disease: managing anaemia, 2015. Available at: https://www.nice.org.uk/guidance/ng8/resources/chronic-kidney-disease-managing-anaemia-51046844101. Accessed on 01/04/2017.
14. Urrechaga E. Clinical utility of the new Beckman-Coulter parameter red blood cell size factor in the study of erythropoiesis. Int J Lab Haematol 2009; 31: 623-9.
15. Dignass AU, Gasche C, Bettenworth D., et al.; European Crohn's and Colitis Organisation [ECCO]. European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. J Crohn Colitis 2015; 9: 211-22.
16. Goodnough LT, Maniatis A, Earnshaw P., et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth 2011; 106: 13-22.
17. Kotzé A, Harris A, Baker C, et al. British Committee for Standards in Haematology Guidelines on the Identification and Management of Pre-Operative Anaemia. Br J Haematol 2015; 171: 322-31.
18. Locatelli F, Bárány P, Covic A, et al.; ERA-EDTA ERBP Advisory Board. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013; 28: 1346-59.
19. Ponikowski P, Voors AA, Anker S.D., et al. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 18: 891-975.
20. Goodnough LT, Comin-Colet J, Leal-Noval S, et al. Management of anemia in patients with congestive heart failure. Am J Hematol 2017; 92: 88-93.
21. Lichtin AE. Clinical practice guidelines for the use of erythroid-stimulating agents: ASCO, EORTC, NCCN. Cancer Treat Res 2011; 157: 239-48.
22. NCCN. Cancer and chemotherapy-induced anemia, Version 1. 2017. Available at: http://www.nccn.org/professional/physician-gls/pdf/anemia.pdf. Accessed on 07/04/2017.
23. Schrijvers D, De Samblanx H, Roila F; ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 2010; 21 (Suppl 5): v244-7.
24. Pratt JJ, Khan KS Non-anaemic iron deficiency - a disease looking for recognition of diagnosis: a systematic review. Eur J Haematol 2016; 96: 618-28.
25. Cook JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol 2005; 18: 319-32.
26. Krayenbuehl PA, Battegay E, Breymann C., et al. Intravenous iron for the treatment of fatigue in non-anemic, premenopausal women with low serum ferritin concentration. Blood 2011; 118: 3222-7.
27. Sharma R, Stanek JR, Koch T.L., et al. Intravenous iron therapy in non-anemic iron-deficient menstruating adolescent females with fatigue. Am J Hematol 2016; 91: 973-7.
28. Burden RJ, Morton K, Richards T., et al. Is iron treatment beneficial in, iron-deficient but non-anaemic (IDNA) endurance athletes? A systematic review and meta-analysis. Br J Sports Med 2015; 49: 1389.
29. Vaucher P, Druais PL, Waldvogel S, Favrat B. Effect of iron supplementation on fatigue in non-anemic menstruating women with low ferritin: a randomized controlled trial. CMAJ 2012; 184: 1247-54.
30. Pittori C, Buser A, Gasser U.E., et al. A pilot iron substitution programme in female blood donors with iron deficiency without anaemia. Vox Sang 2011; 100: 303-11.
31. th, Utermohlen V, Hinton PS, et al. Marginal iron deficiency without anemia impairs aerobic adaptation among previously untrained women. Am J Clin Nutr 2002; 75: 734-42.
32. Hinton PS, Giordano C, Brownlie T., Haas JD. Iron supplementation improves endurance after training in iron-depleted, nonanemic women. J Appl Physiol 2000; 88: 1103-11.
33. Hinton PS, Sinclair LM Iron supplementation maintains ventilatory threshold and improves energetic efficiency in iron-deficient nonanemic athletes. Eur J Clin Nutr 2007; 61: 30-9.
34. Brutsaert TD, Hernandez-Cordero S, Rivera J., et al. Iron supplementation improves progressive fatigue resistance during dynamic knee extensor exercise in iron-depleted, nonanemic women. Am J Clin Nutr 2003; 77: 441-8.
35. Drukker L, Hants Y, Farkash R., et al. Iron deficiency anemia at admission for labor and delivery is associated with an increased risk for Cesarean section and adverse maternal and neonatal outcomes. Transfusion 2015; 55: 2799-806.
36. Congdon EL, Westerlund A, Algarin C.R., et al. Iron deficiency in infancy is associated with altered neural correlates of recognition memory at 10 years. J Pediatr 2012; 160: 1027-33.
37. Peña-Rosas J.P., De-Regil LM, Garcia-Casal MN, et al. Daily oral iron supplementation during pregnancy. Cochrane Database Syst Rev 2015; 7: CD004736.
38. Peña-Rosas J.P., De-Regil LM, Dowswell T., et al. Intermittent oral iron supplementation during pregnancy. Cochrane Database Syst Rev 2015; 10: CD009997.
39. Stein J, Connor S, Virgin G., et al. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol 2016; 22: 7908-25.
40. Muñoz M., Botella-Romero F, Gómez-Ramírez S, et al. Iron deficiency and anaemia in bariatric surgical patients: causes, diagnosis and proper management. Nutr Hosp 2009; 24: 640-54.
41. Simanek R, Vormittag R, Ay C., et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010; 8: 114-20.
42. Novacek G, Weltermann A, Sobala A., et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139: 779-87.
43. Evstatiev R, Bukaty A, Jimenez K., et al. Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin. Am J Hematol 2014; 89: 524-9.
44. Jimenez K, Khare V, Evstatiev R., et al. Increased expression of HIF2α during iron deficiency-associated megakaryocytic differentiation. J Thromb Haemost 2015; 13: 1113-27.
45. Kulnigg-Dabsch S., Schmid W, Howaldt S., et al. Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial. Inflamm Bowel Dis 2013; 19: 1609-16.
46. Henry DH, Dahl NV, Auerbach MA Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol 2012; 87: 308-10.
47. Hazara AM, Bhandari S. Intravenous iron infusion reduces platelet counts in patients with chronic kidney disease. J Clinical Pharm Ther 2015; 40: 20-3.
48. Kaiafa G, Savopoulos C, Kanellos I., et al. Anemia and stroke: where do we stand? Acta Neurol Scand 2017; 135: 596-602.
49. Harju E. Empty iron stores as a significant risk factor in abdominal surgery. J Parenteral Enteral Nut 1988; 12: 282-5.
50. Piednoir P, Allou N, Driss F., et al. Preoperative iron deficiency increases transfusion requirements and fatigue in cardiac surgery patients: a prospective observational study. Eur J Anaesthesiol 2011; 28: 796-801.
51. Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol 1973; 26: 770-2.
52. Beris P, Muñoz M, García-Erce JA, et al. Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth 2008; 100: 599-604.
53. Bisbe E, Moltó L, Arroyo R, et al. Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty. Br J Anaesth 2014; 113: 402-9.
54. Cuenca J, Garcia-Erce JA, Martinez F., et al. Preoperative haematinics and transfusion protocol reduce the need for transfusion after total knee replacement. Int J Surg 2007; 5: 89-94.
55. Lachance K, Savoie M, Bernard M., et al. Oral ferrous sulfate does not increase preoperative hemoglobin in patients scheduled for hip or knee arthroplasty. Ann Pharmacother 2011; 45: 764-70.
56. Kotze A, Carter LA, Scally AJ Effect of a patient blood management programme on preoperative anaemia, transfusion rate, and outcome after primary hip or knee arthroplasty: a quality improvement cycle. Br J Anaesth 2012; 108: 943-52.
57. Muñoz M., Gómez-Ramírez S, Campos A, et al. Pre-operative anaemia: prevalence, consequences and approaches to management. Blood Transfus 2015; 13: 370-9.
58. García-Erce J.A., Cuenca J, Martínez F, et al. Perioperative intravenous iron preserves iron stores and may hasten the recovery from post-operative anaemia after knee replacement surgery. Transfus Med 2006; 16: 335-41.
59. ®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang 2015; 109: 257-66.
60. Vaglio S, Prisco D, Biancofiore G., et al. Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. Blood Transfus 2016; 14: 23-65.
61. Chaplin S, Bhandari S. Oral Iron properties and current place in the treatment of anaemia. Prescriber 2012; 6: 12-8.
62. Schrier SL, Auerbach M. Treatment of iron deficiency anemia in adults. UpToDate 2017. Available at: https://www.uptodate.com/contents/treatment-of-iron-deficiency-anemia-in-adults. Accessed on 22/04/2017.
63. Ferrari P, Nicolini A, Manca M.L., et al. Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate. Biomed Pharmacother 2012; 66: 414-8.
64. Gasche C, Ahmad T, Tulassay Z., et al.; AEGIS Study Group Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis 2015; 21: 579-88.
65. Schmidt C, Ahmad T, Tulassay Z., et al.; AEGIS Study Group. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a phase 3 study. Aliment Pharmacol Ther 2016; 44: 259-70.
66. Mafodda A, Giuffrida D, Prestifilippo A., et al. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoietin alpha: a phase II prospective multicenter study. Support Care Cancer 2017; doi: 10.1007/s00520-017-3690-z. [Epub ahead of print].
67. Pisani A, Riccio E, Sabbatini M., et al. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant 2015; 30: 645-52.
68. Tolkien Z, Stecher L, Mander A.P., et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One 2015; 10: e0117383.
69. Moretti D, Goede JS, Zeder C, et al Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood 2015; 126: 1981-9.
70. Muñoz M., García-Erce JA, Remacha AF. Disorders of iron metabolism. Part 1: molecular basis of iron homoeostasis. J Clin Pathol 2011; 64: 281-6.
71. Rimon E, Kagansky N, Kagansky M., et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med 2005; 118: 1142-7.
72. Gisbert JP, Bermejo F, Pajares R., et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis 2009; 15: 1485-91.
73. Leal-Noval S.R., Muñoz M, Asuero M., et al. Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document". Blood Transfus 2013; 11: 585-610.
74. NICE guidance. Blood Transfusion. Available at: https://www.nice.org.uk/guidance/ng24/resources/blood-transfusion-1837331897029. Accessed on 15/04/2017.
75. Klein AA, Arnold P, Bingham R.M., et al. AAGBI guidelines: the use of blood components and their alternatives 2016. Anaesthesia 2016; 71: 829-42.
76. Muñoz M., Breymann C, García-Erce JA, et al. Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox Sang 2008; 94: 172-83.
77. Auerbach M, Muñoz M. Intravenous iron for treating cancer-induced anemia: meeting an unmet need? Chin Clin Oncol 2012; 1: 21-3.
78. Muñoz M., García-Erce JA, Cuenca J, et al. On the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic surgery. Blood Transfus 2012; 10: 8-22.
79. Avni T, Bieber A, Grossman A., et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clinic Proc 2015; 90: 12-23.
80. Shepshelovich D, Rozen-Zvi B, Avni T., et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. Am J Kidney Dis 2016; 68: 677-90.
81. Bhandari S, Brownjohn A, Turney J. Effective utilisation of erythropoietin with intravenous iron therapy. J Clin Pharmacol Ther 1998; 23: 73-8.
82. Auerbach M, Adamson J, Bircher A., et al. On the safety of intravenous iron, evidence trumps conjecture. Haematologica 2015; 100: e214-5.
83. Ben-Assa E., Shacham Y, Shashar M., et al. Target hemoglobin may be achieved with intravenous iron alone in anemic patients with cardiorenal syndrome: an observational study. Cardiorenal Med 2015; 5: 246-53.
84. Quintana-Díaz M, Muñoz-Romo R, Gómez-Ramírez S, et al. A fast-track anaemia clinic in the Emergency Department: cost-analysis of intravenous iron administration for treating iron-deficiency anaemia. Blood Transfus 2017; 15: 438-46.
85. Morhaim D, Auerbach M. Iron-deficiency anaemia in the emergency room: a new opportunity for the use of intravenous iron. Blood Transfus 2016; 14: 91-2.
86. Aapro M, Österborg A, Gascón P, et al. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 2012; 23: 1954-62.
87. Theusinger OM, Kind SL, Seifert B, et al Patient blood management in orthopaedic surgery - a four year follow up from 2008 to 2011 at the Balgrist University Hospital in Zurich, Switzerland on transfusion requirements and blood loss. Blood Transfus 2014; 12: 195-203.
88. Nielsen OH, Coskun M, Weiss G. Iron replacement therapy: do we need new guidelines? Curr Opin Gastroenterol 2016; 32: 128-35.
89. Kulnigg S, Teischinger L, Dejaco C., et al. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol 2009; 104: 1460-7.
90. Evstatiev R, Alexeeva O, Bokemeyer B., et al.; FERGI Study Group. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 269-77.
91. Parrott J, Frank L, Rabena R., et al. American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients. Surg Obes Relat Dis 2017; 13: 727-41.
92. Mechanick JI, Youdim A, Jones D.B., et al.; American Association of Clinical Endocrinologists; Obesity Society; American Society for Metabolic & Bariatric Surgery. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic and Bariatric Surgery. Endocr Pract 2013; 19: 337-72.
93. Kalra PA, Bhandari S. Safety of intravenous iron use in chronic kidney disease. Curr Opin Nephrol Hypertens 2016; 25: 529-35.
94. Rottembourg J, Kadri A, Leonard E., et al. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant 2011; 26: 3262-7.
95. Rottembourg J, Guerin A, Diaconita M., Kadri A. The complete study of the switch from iron-sucrose originator to iron-sucrose similar and vice versa in hemodialysis patients. J Kidney 2016; 2: 1-7.
96. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product. EMA/CHMP/SWP/620008/2012. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2015/03/WC500184922.pdf; Accessed on 17/03/2017.
97. Danielson BG, Structure, chemistry and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004; 15: S93-8.
98. Jahn MR, Andreasen HB, Fütterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011; 78: 480-91.
99. Bhandari S. Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice. Ther Clin Risk Manag 2011; 7: 501-9.
100. Wilson PD, Hutchings A, Jeans A., Macdougall IC. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic. J Med Econ 2013; 16: 108-14.
101. Calvet X, Ruíz MÀ, Dosal A, et al. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency. PLoS One 2012; 7: e45604.
102. Calvet X, Gene E, Ruiz M.A., et al. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia. Technol Health Care 2016; 24: 111-20.
103. Quintana-Díaz M, Fabra-Cadenas S, Gómez-Ramírez S, et al. A fast-track anaemia clinic in the Emergency Department: feasibility and efficacy of intravenous iron administration for treating sub-acute iron deficiency anaemia. Blood Transfus 2016; 14: 126-33.
104. European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron containing medicines. EMA/579491/2013. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/IV-iron-31/WC500151308.pdf. Accessed on 18/01/2017.
105. Rampton D, Folkersen J, Fishbane S., et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 2014; 99: 1671-6.
106. Macdougall IC, Bircher AJ, Eckardt K.U., et al.; Conference Participants. Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2016; 89: 28-39.
107. Dermann R, Roman E, Modiano M.R., et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol 2017; 92: 286-91.
108. Mahey R, Kriplani A, Mogili K.D., et al. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. Int J Gynaecol Obstet 2016; 133: 43-8.
109. Bisbe E, García-Erce JA, Díez-Lobo AI, Muñoz M; Anaemia Working Group España. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth 2011; 107: 477-8.
110. Evstatiev R, Marteau P, Iqbal T., et al.; FERGI Study Group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141: 846-53.
111. Macdougall IC, Strauss WE, McLaughlin J, et al A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol 2014; 9: 705-12.
112. Strauss WE, Dahl NV, Li Z, et al Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemia. BMC Hematol 2016; 16: 20.
113. Pfenniger A, Schuller C, Christoph P., Surbek D. Safety and efficacy of high-dose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia. J Perinat Med 2012; 40: 397-402.
114. Wang C, Graham DJ, Kane R.C., et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015; 314: 2062-8.
115. DeLoughery TG, Auerbach M. Is low-molecular weight iron dextran really the most risky iron?-Unconvincing data from an unconvincing study. Am J Hematol 2016; 91: 451-2.
116. Wysowski DK, Swartz L, Borders-Hemphill BV, et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol 2010; 85: 650-4.
117. Bolton-Maggs P.H., Cohen H. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol 2013; 163: 303-14.
118. Bager P, Hvas CL, Dahlerup JF Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol 2017; 83: 1118-25.
119. Prats M, Font R, García C, et al. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study. BMC Nephrol 2013; 14: 167.
120. Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol 2015; 2015: 468675.
121. Schaefer B, Würtinger P, Finkenstedt A., et al. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS One 2016; 11: e0167146.
122. Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010; 2010: 338-47.
123. Barton JC, Barton EH, Bertoli L.F., et al. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med 2000; 109: 27-32.
124. Bircher A, Auerbach M. Hypersensitivity from intravenous iron products. Immunol Allergy Clin N Am 2014; 34: 707-23.
125. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007; 369: 1502-4.
126. Fishbane S, Ungureanu VD, Maesaka J.K., et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28: 529-34.
127. Syed A, Bhandari S. Correction of iron deficiency anaemia using IV CosmoFer in CKD patients with asthma: a prospective study. QJM 2016; 109: 187-90.
128. Auerbach M, Chaudhry M, Goldman H., Ballard H. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. J Lab Clin Med 1998; 131: 257.
129. Auerbach M, Deloughery T. Single-dose intravenous iron for iron deficiency: a new paradigm. Hematology Am Soc Hematol Educ Program 2016; 2016: 57-66.
130. Ganz T. Iron in innate immunity: starve the invaders. Curr Opin Immunol 2009; 21: 63-7.
131. Litton E, Xiao J, Ho KM Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. Br Med J 2013; 347: f4822.
132. Muñoz M., Auerbach M, Shander A. Re: Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ (13 September 2013) Available at: http://www.bmj.com/content/347/bmj.f4822/rr/661826. Accessed on 18/01/2017.
133. Torres S, Kuo YH, Morris K, et al Intravenous iron following cardiac surgery does not increase the infection rate. Surg Infect (Larchmt) 2006; 7: 361-6.
134. Muñoz M., Gómez-Ramírez S, Cuenca J, et al. Very-short-term perioperative intravenous iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients. Transfusion 2014; 54: 289-99.
135. Andrews SC, Robinson AK, Rodríguez-Quiñones F. Bacterial iron homeostasis. FEMS Microbiol Rev 2003; 27: 215-37.
136. Brookhart MA, Freburger JK, Ellis A.R., et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013; 24: 1151-8.
137. Agarwal R, Kusek JW, Pappas MK A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015; 88: 905-94.
138. Macdougall IC, Bock AH, Carrera F, et al.; FIND-CKD Study Investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29: 2075-84.
139. Shepshelovich D, Rozen-Zvi B, Avni T., et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. Am J Kidney Dis 2016; 68: 677-90.
140. Kalantar-Zadeh K., Regidor DL, McAllister C.J., et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-80.
141. Kshirsagar AV, Freburger JK, Ellis A.R., et al. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One 2013; 8: e78930.
142. EU Clinical Trials Register. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002267-25/GB. Accessed on 17/01/2017.
143. Weiss G. Anemia of chronic disorders: new diagnostic tools and new treatment strategies. Semin Hematol. 2015; 52: 313-20.
144. Maccio A, Madeddu C, Gramignano G., et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica 2015; 100: 124-32.
145. Schrijvers D, De Samblanx H, Roila F. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 2010; 21 (Suppl 5): v244-7.
146. Auerbach M. Should intravenous iron be the standard of care in oncology? J Clin Oncol 2008; 26: 1579-81.
147. Gafter-Gvili A., Steensma DP, Auerbach M. Should the ASCO/ ASH guidelines for the use of intravenous iron in cancer- and chemotherapy-induced anemia be updated? J Natl Compr Canc Netw 2014; 12: 657-64.
148. Mhaskar R, Wao H, Miladinovic B., et al. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev 2016; 2: CD009624.
149. Hedenus M, Birgegard G, Nasman P., et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21: 627-32.
150. Hedenus M, Nasman P, Liwing J. Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. J Clin Pharm Ther 2008; 33: 365-74.
151. Ludwig H, Evstatiev R, Kornek G., et al. Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr 2015; 127: 907-19.
152. Nagaraju SP, Cohn A, Akbari A., et al. Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial. BMC Nephrol 2013; 14: 64.
153. Pisani A, Riccio E, Sabbatini M., et al. Effect of oral liposomal iron versus intravenous iron for the treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant 2015; 30: 645-52.
154. Douglas Rizzo J., Brouwers M, Hurley P., et al. ASCO-ASH update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010; 28: 4996-5010.
155. MHRA Public Assessment Report. Epoetins for the management of anaemia associated with cancer: risk of tumour progression and mortality, 2007. Available at: http://www.mhra.gov.uk/home/groups/s-par/documents/websiteresources/con2033214.pdf. Accessed on 13/04/2014.
156. Pfeffer MA, Burdmann EA, Chen C.Y., et al.; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-32.
157. Palmer SC, Navaneethan SD, Craig J.C., et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33.
158. Streja E, Kovesdy CP, Greenland S et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for haemoglobin-survival paradox in haemodialysis. Am J Kidney Dis 2008; 52: 727-36.
159. Weber EW, Slappendel R, Hémon Y, et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 2005; 22: 249-57.
160. So-Osman C., Nelissen RG, Koopman-van Gemert AW, et al. Patient blood management in elective total hip- and knee-replacement surgery (Part 1): a randomized controlled trial on erythropoietin and blood salvage as transfusion alternatives using a restrictive transfusion policy in erythropoietin-eligible patients. Anesthesiology 2014; 120: 839-51.
161. Gonzalez-Porras J.R., Colado E, Conde M.P., et al. An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus Med 2009; 19: 35-42.
162. Basora M, Colomina MJ, Tio M, et al Optimizing preoperative haemoglobin with intravenous iron. Br J Anaesth 2013; 110: 488-90.
163. Kim YT, Kim SW, Yoon B.S., et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007; 105: 199-204.
164. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010; 116: 522-5.
165. Athibovonsuk P, Manchana T, Sirisabya N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol 2013; 131: 679-82.
166. Steinmetz T, Tschechne B, Harlin O., et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013; 24: 475-82.
167. Muñoz M., Gomez-Ramirez S, Martin-Montañez E, Auerbach M. Perioperative anemia management in colorectal cancer patients: a pragmatic approach. World J Gastroenterol 2014; 20: 1972-85.
168. Calleja JL, Delgado S, del Va l A, et al. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Int J Colorectal Dis 2016; 31: 543-51.
169. Froessler B, Palm P, Weber I., et al. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. Ann Surg 2016; 264: 41-6.
170. Keeler BD, Simpson JA, Ng O, et al.; on behalf of the IVICA Trial Group. Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer. Br J Surg 2017; 104: 214-21.